

Figure S1. Anticancer drug screening assay using epithelial cells isolated from PDC1. Boxplot represents the results relative to the reference samples. Empty circles represent outliers of the reference samples. X represents the AUC value in PDC1. PDC, patient-derived cells; AUC, area under the curve.




Figure S2. Anticancer drug screening assay using epithelial cells isolated from PDC2. Boxplot represents the results relative to the reference samples. Empty circles represent outliers of the reference samples. X represents the AUC value in PDC2. PDC, patient-derived cells; AUC, area under the curve.



Figure S3. Anticancer drug screening assay using epithelial cells isolated from PDC3. Boxplot represents the results relative to the reference samples. Empty circles represent outliers of the reference samples. X represents the AUC value in PDC3. PDC, patient-derived cells; AUC, area under the curve.




Figure S4. Anticancer drug screening assay using epithelial cells isolated from PDC4. Boxplot represents the results relative to the reference samples. Empty circles represent outliers of the reference samples. X represents the AUC value in PDC4. PDC, patient-derived cells; AUC, area under the curve.




Table SI. Effective drugs for each PDC.

	Drug	Target	Z-score
PDC1	Bortezomib (Velcade)	Proteasome	-0.748
	AZD2014	mTOR	-0.631
	AZD5363	Akt1/2/3	-0.626
	Carfilzomib	Proteasome	-0.601
PDC2	PF-05212384 (PKI-587)	P3k/mTOR	-1.872
	Neratinib (HKI-272)	EGFR	-1.778
	Panobinostat (LBH589)	HDAC	-1.429
	Axitinib	VEGFR1/2/3, PDGFRb, c-Kit	-1.355
	5-FU (5-Fluoracil)		-1.212
	Sunitinib Malate (Sutent)	VEGFR2, PDGFRb	-1.192
	CO-1686	EGFR	-1.16
	BGJ398 (NVP-BGJ398)	FGFR1/2/3	-1.026
	BKM120 (NVP-BKM120)	PI3K	-1.013
	AZD6244 (Selumetinib)	MEK1	-0.907
	Foretinib (XL880)	HGFR, VEGFR	-0.903
	Dovitinib (TKI-258)	Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRa/b	-0.882
	Dabrafenib	BRAFV600	-0.809
	AZD4547	FGFR1/2/3	-0.802
	Carfilzomib	Proteasome	-0.66
PDC3	5-FU		-1.638
	Oxaliplatin		-1.596
	ABT-199 (GDC-0199)	Bcl-2	-1.472
	Afatinib (BIBW2992)	EGFR	-1.335
	Lapatinib	EGFR	-1.228
	Imatinib (Gleevec)	v-Abl, c-Kit, PDGFR	-1.178
	CI-1033 (Canertinib)	EGFR, HER-2	-1.121
	Dacomitinib (PF299804_PF-00299804)	EGFR	-1.096
	Carfilzomib	Proteasome	-1.034
	Gefitinib (Iressa)	EGFR	-1.013
PDC4		No drugs were sensitive.	

PDC; patient-derived cancer cell; EGFR, epidermal growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptor; Flt3, fms related tyrosine kinase 3; MEK, MAP Kinase 1; HGFR, hepatocyte growth factor receptor.